Search Results

Displaying Results 276-294 of 294 "'INT'"

Jul 21, 2025, 19:30 ET Eisai to Present Four-Year Efficacy and Safety Data on Continuous Treatment with Lecanemab at The Alzheimer’s Association International Conference

10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.U.S. Food and Drug Administration. 2023. FDA Converts

More news about: Eisai Inc.


Jul 16, 2025, 17:31 ET Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of XOLAIR in Adults, PALFORZIA in Toddlers and Expected Entry of Viaskin Peanut Patches | DelveInsight

(Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual Immunotherapy-Tablet), InnoUp Farma (INP20), Allergy Therapeutics (VLP Peanut), Intrommune Therapeutics (INT301), Regeneron Pharmaceuticals (Linvoseltamab + Dupilumab), and others. LAS VEGAS,

More news about: DelveInsight Business Research, LLP


Jul 16, 2025, 07:01 ET Bcore Unveils Unified Brand to Power the Nation's Most Complex Missions

and tradecraft with cutting-edge technical capabilities, including: Advanced software development and DevSecOpsMulti-INT data science and geospatial intelligenceAI/ML and novel analyticsCloud architecture and engineeringMission consulting and

More news about: Bcore


Jul 08, 2025, 08:00 ET Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

www.tac.org/reports_publications/schizophrenia-fact-sheet/. iii Alphs L, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable therapy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125 iv Lafeuille MH, Gravel J, Lefebvre P, et al. Patterns

More news about: Johnson & Johnson


Jun 30, 2025, 11:02 ET Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

the first patients treated with INT230-6 in its Phase 2 INVINCIBLE-4 trial for early-stage triple-negative breast cancer showed high levels of tumor necrosis after just two injections—prior to beginning standard immunochemotherapy. "We are excited to see that INT230-6 is achieving meaningful levels

More news about: USA News Group


Jun 30, 2025, 08:00 ET Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

"MPNST is the first neurological-specific tumor for which INT230-6 has been used. We are pleased to see that INT230-6 achieved meaningful results in MPMNST that are similar to the results we saw in other in vivo models where INT230-6 has been tested," said Lewis H. Bender,

More news about: Intensity Therapeutics Inc.


Jun 26, 2025, 08:50 ET Estudio confirma eficacia de MolecuLight en detección bacteriana para un mejor tratamiento de las heridas

S, Moore Z, Patton D, O'Connor T, Derwin R. The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds: A Systematic Review. Int Wound J. 2025;22(6):e70678. 2 Le

More news about: MolecuLight Inc.


Jun 26, 2025, 06:13 ET Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management

S, Moore Z, Patton D, O'Connor T, Derwin R. The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds: A Systematic Review. Int Wound J. 2025;22(6):e70678. 2

More news about: MolecuLight


Jun 26, 2025, 06:13 ET Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management

S, Moore Z, Patton D, O'Connor T, Derwin R. The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds: A Systematic Review. Int Wound J. 2025;22(6):e70678. 2

More news about: MolecuLight Inc.


Jun 26, 2025, 06:13 ET Wegweisende Studie bestätigt die Wirksamkeit von MolecuLight bei der bakteriellen Echtzeit-Detektion für ein verbessertes Wundmanagement

Patton D, O'Connor T, Derwin R. The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds: Eine systematische Überprüfung. Int Wound J. 2025;22(6):e70678. 2 Le

More news about: MolecuLight Inc.


Jun 26, 2025, 06:13 ET Une étude importante confirme l'efficacité de MolecuLight dans la détection bactérienne en temps réel pour une meilleure gestion des plaies

Moore Z, Patton D, O'Connor T, Derwin R. The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds : Une revue systématique. Int Wound J. 2025;22(6):e70678. 2 Le

More news about: MolecuLight Inc.


Jun 24, 2025, 10:28 ET Peanuts Provide Much-needed Protein for GLP-1 Users

ameliorates high-fat diet-induced atherosclerosis by regulating lipid metabolism, inflammation reaction and gut microbiota in ApoE-/- mice. Food Res Int. 2022 Apr;154:111014. doi: 10.1016/j.foodres.2022.111014. Epub 2022 Feb 16.

More news about: The Peanut Institute


Jun 24, 2025, 08:01 ET Stuart Therapeutics Announces Initial Results of Phase III Clinical Trial for ST-100 (Vezocolmitide) Ophthalmic Solution, a Novel Dry Eye Disease Candidate

E.; Calkins, D.J. Intraocular Delivery of a Collagen Mimetic Peptide Repairs Retinal Ganglion Cell Axons in Chronic and Acute Injury Models (2022). Int. J. Mol. Sci.  23:2911,

More news about: Stuart Therapeutics


Jun 24, 2025, 06:02 ET 全新SKINVIVE® 昇光針® 矚目登場 -- 引領突破水光界限

brand of hyaluronic acid facial fillers claim. Mar 2023. 6. Allergan Unpublished Data. INT-VOT-2050006. Juvederm VOLITE laboratory testing: hydration and elasticity, mouldability, tissue integration, spreadability. May 2020.

More news about: Allergan Aesthetics


Jun 20, 2025, 21:02 ET CHAI - AI Lab Quantizes Social AI to 4-bit for +56% Increase in Throughput

parameters, has emerged as a key strategy for optimizing LLMs. CHAI's research team systematically evaluated multiple quantization approaches (including INT8, FP16, and hybrid methods) to maximize efficiency without sacrificing output quality. The winning implementation: 56% faster

More news about: Chai AI


Jun 20, 2025, 09:21 ET With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC). "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune

More news about: USA News Group


Jun 20, 2025, 05:13 ET 全新SKINVIVE® 昇光針® 矚目登場 -- 引領突破水光界限

brand of hyaluronic acid facial fillers claim. Mar 2023. 6. Allergan Unpublished Data. INT-VOT-2050006. Juvederm VOLITE laboratory testing: hydration and elasticity, mouldability, tissue integration, spreadability. May 2020.

More news about: Allergan Aesthetics


Jun 19, 2025, 08:00 ET Johnson & Johnson Launches VOLT™ Wrist and Proximal Humerus Plating Systems in the U.S.

Norris BL, et al. Epidemiology of proximal humerus fractures in the United States: a population-based study. JSES Int. 2024;8(2):331-337. doi:10.1016/j.jseint.2024.02.005.13 Launonen AP, Lepola V, Saranko A, Flinkkilä T, Laitinen M, Mattila VM.

More news about: Johnson & Johnson MedTech


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.